Proceedings of the National Academy of Sciences · 1994 · 143 citations · 19 references
Life SciencesNeurobiologyNeuroscienceEnzymologyMolecular NeurobiologyMolecular NeuroscienceEnzyme InhibitionNeuromuscular JunctionNeurotransmissionProteolytic EnzymesProteolytic ProcessingSynaptic TransmissionProtease InhibitionProtease InhibitorsProteolytic ActivityProteolytic Enzyme ActivityProteolytic PathwaysRegulation By Serine Protease InhibitorsSerine Protease MechanismThrombin Inhibition
Molecular mechanisms of activity-dependent synapse reduction were studied in an in vitro mammalian neuromuscular preparation. Synapse reduction in this model is activity-dependent and is substantially reduced by the broad-spectrum protease inhibitor, leupeptin, suggesting the role of activity-dependent proteolytic action in the process. Our present experiments show that a potent and specific thrombin inhibitor, hirudin, at nanomolar concentration completely blocked the activity-dependent synapse reduction. Furthermore, a naturally occurring serine protease inhibitor, protease nexin I (PNI), which closely colocalizes with acetylcholine receptors at the neuromuscular junction, inhibited the synapse reduction at the same low concentration. In contrast, neither cystatin, a cysteine protease inhibitor, nor aprotinin, a serine protease inhibitor that does not inhibit thrombin, blocked the synapse reduction. Similarly, neither of the inhibitors of the calcium-activated proteases calpain I and II prevented the reduction of synapses. These results strongly suggest that serine proteolytic action by thrombin or thrombin-like molecules is required for synapse reduction in our in vitro model of the mammalian neuromuscular junction.
19
Prothrombin mRNA is expressed by cells of the nervous system
Melitta Dihanich, Matthew R. Kaser, Eva Reinhard et al. · Neuron · 1991 · 339 citations